Navigation Links
Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
Date:1/11/2008

SEATTLE, Jan. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that the Commissione Nazionale per le Societa e la Borsa ("CONSOB") granted authorization to publish the Italian listing prospectus, according to the procedures set forth by Article 8 and Article 56 of the CONSOB Regulation no. 11971/99, relating to offerings of CTI's common stock representing more than 10% of the shares of common stock currently outstanding pursuant to the Step-Up Equity Financing Agreement by and between Societe Generale and CTI, subject to the inclusion of certain additional information in the prospectus.

Societe Generale has agreed to purchase, over a period of time through January 2009, up to 60 million Euros worth of shares of CTI's common stock. Any shares issued, which are covered under an existing shelf registration, will be purchased by Societe Generale, which will sell the shares on the Italian market. Societe Generale's obligation to purchase shares upon request by CTI is subject to the conditions set forth in the agreement with the bank.

Subject to certain conditions, the Step-up Equity Financing Agreement will allow CTI to raise equity finance in one or more tranches. All issuances are at CTI's election, and CTI is not required to undertake any issuances under the agreement. The total amount of any capital raised will depend on the actual financing needs over the lifetime of the agreement and other considerations and will reflect the market performance and trading volume of CTI shares.

As soon as published, the listing prospectus will be available in hard copy form at CTI's office in Italy at Via Ariosto, 23, 20091 Bresso (MI) and at the head office of Borsa Italiana S.p.A. at Piazza degli Affari, 6, Milan; and in electronic form on CTI's web site (http://www.cticseattle.com).

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of such jurisdiction. A prospectus related to shares of CTI common stock, including any subsequently filed prospectus supplement relating to any specific issuance of shares, may be obtained for free by visiting EDGAR on the SEC Web site at http://www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in such offering will arrange to send you the prospectus if you request it by contacting CTI at the investor contact address below.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These forward looking statements include statements regarding CTI's ability to meet the conditions necessary to raise funds under the step-up equity financing agreement, the conditions to effectiveness of the step-up financing agreement being satisfied, the amount of any eventual proceeds from the step-up equity financing agreement, and the sufficiency of any such funds to meet CTI's capital requirements. The risks and uncertainties include the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, Form 10-Q and 8-K. Except as may be required by Italian law, CTI assumes no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
2. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
3. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
4. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
5. ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
6. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
7. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
8. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
9. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
10. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission ... hardware projects are designed, built and brought to market. , The Design Lab ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology:
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
Breaking Biology News(10 mins):